Macrolide and Ketolide Resistance with Streptococcus pneumoniae

Medical Clinics of North America

Volumn 90, Issue 6, 2006, Pages 1109-1124

  Doern, Gary V ^a,b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; KETOLIDE; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; TETRACYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHEMICAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TREATMENT FAILURE; DRUG USE; GASTROINTESTINAL TOXICITY; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; NORTH AMERICA; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ACTIVITY RELATION; TREATMENT FAILURE; UNITED STATES;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BACTERIAL PROTEINS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; HUMANS; KETOLIDES; MACROLIDES; MEMBRANE PROTEINS; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 33750977812     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2006.07.010     Document Type: Review

References (79)

1. Nightingale C.H. Macrolides: new questions, new insights. Infect Med 15 Suppl A (1998) 8-9
2. Balfour J.A.B., and Figgitt D.P. Telithromycin. Drugs 61 6 (2001) 815-829
3. Doern G.V., Heilmann K.P., Huynh H.K., et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 45 6 (2001) 1721-1729
4. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement: approved standard M100-S15 (2005), CLSI, Wayne, PA
5. Leclercq R., and Courvalin P. Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother 46 9 (2002) 2727-2734
6. Roberts M.C., Sutcliffe J., Courvalin P., et al. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother 43 12 (1999) 2823-2830
7. Farrell D.J., Morrissey I., Bakker S., et al. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations. Antimicrob Agents Chemother 48 8 (2004) 3169-3171
8. Farrell D.J., Douthwaite S., Morrissey I., et al. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study. Antimicrob Agents Chemother 47 6 (2003) 1777-1783
9. Canu A., Malbruny B., Coquemont M., et al. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 46 1 (2002) 125-131
10. Tait-Kamradt A., Davies T., Appelbaum P.C., et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 44 12 (2000) 3395-3401
11. Davies T.A., Bush K., Sahm D., et al. Predominance of 23S rRNA mutants among non-erm, non-mef macrolide-resistant clinical isolates of Streptococcus pneumoniae collected in the United States in 1999-2000. Antimicrob Agents Chemother 49 7 (2005) 3031-3033
12. Reinert R.R., Wild A., Appelbaum P., et al. Ribosomal mutations conferring resistance to macrolides in Streptococcus pneumoniae clinical strains isolated in Germany. Antimicrob Agents Chemother 47 7 (2003) 2319-2322
13. Pihlajamäki M., Kataja J., Seppälä H., et al. Ribosomal mutations in Streptococcus pneumoniae clinical isolates. Antimicrob Agents Chemother 46 3 (2002) 654-658
14. Wolter N., Smith A.M., Farrell D.J., et al. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the Pneumococcus. Antimicrob Agents Chemother 49 8 (2005) 3554-3557
15. Jones R.N., Farrell D.J., and Morrissey I. Quinupristin-dalfopristin resistance in Streptococcus pneumoniae: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 47 8 (2003) 2696-2698
16. Waites K., Johnson C., Gray B., et al. Use of clindamycin disks to detect macrolide resistance mediated by ermB and mefE in Streptococcus pneumoniae isolates from adults and children. J Clin Microbiol 38 5 (2000) 1731-1734
17. Shortridge V., Doern G.V., Brueggemann A.B., et al. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis 29 (1999) 1186-1188
18. Farrell D.J., and Jenkins S.G. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002. J Antimicrob Chemother 54 Suppl. S1 (2004) i17-i22
19. Reinert R.R., van der Linder M., and Al-Lahham A. Molecular characterization of the first telithromycin-resistant Streptococcus pneumoniae isolate in Germany. Antimicrob Agents Chemother 49 8 (2005) 3520-3522
20. Rantala M., Haanperä-Heikkinen M., Lindgren M., et al. Streptococcus pneumoniae isolates resistant to telithromycin. Antimicrob Agents Chemother 50 5 (2006) 1855-1858
21. Faccone D., Andres P., Galas M., et al. Emergence of a Streptococcus pneumoniae clinical isolate highly resistant to telithromycin and fluoroquinolones. J Clin Microbiol 43 11 (2005) 5800-5803
22. Farrell D.J., and Felmingham D. Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003. Antimicrob Agents Chemother 48 5 (2004) 1882-1884
23. Spika J.S., Facklam R.R., Plikaytis B.D., et al., the Pneumococcal Surveillance Working Group. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. J Infect Dis 163 (1991) 1273-1278
24. Jorgensen J.H., Doern G.V., Maher L.A., et al. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 34 11 (1990) 2075-2080
25. Barry A.L., Pfaller M.A., Fuchs P.C., et al. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from US medical centers in 1992 and 1993. Antimicrob Agents Chemother 38 10 (1994) 2419-2425
26. Doern G.V., Brueggemann A., Holley Jr. H.P., et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 40 5 (1996) 1208-1213
27. Doern G.V., Brueggemann A.B., Huynh H., et al. Antimicrobial resistance with S pneumoniae in the United States, 1997-98. Emerg Infect Dis 5 6 (1999) 757-765
28. Sahm D.F., Karlowsky J.A., Kelly L.J., et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob Agents Chemother 45 4 (2001) 1037-1042
29. Doern G.V., Heilmann K.P., Huynh H.K., et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 45 6 (2001) 1721-1729
30. Thornsberry C., Sahm D.F., Kelly L.J., et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis 34 Suppl 1 (2002) S4-S16
31. Karlowsky J.A., Thornsberry C., Jones M.E., et al. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program. Clin Infect Dis 36 (2003) 963-970
32. Doern G.V., Richter S.S., Miller A., et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antibiotic classes?. Clin Infect Dis 41 (2005) 139-148
33. Simor A.E., Louie M., and Low D.E. Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. The Canadian Bacterial Surveillance Network. Antimicrob Agents Chemother 40 9 (1996) 2190-2193
34. Davidson R.J. Canadian Bacterial Surveillance Network, Low DE. A cross-Canada surveillance of antimicrobial resistance in respiratory tract pathogens. Can J Infect Dis 10 2 (1999) 128-133
35. Zhanel G.G., Karlowsky J.A., Palatnick L., et al. The Canadian Respiratory Infection Study Group. Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian National Surveillance Study. Antimicrob Agents Chemother 43 10 (1999) 2504-2509
36. Low D.E., de Azavedo J., Weiss K., et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother 46 5 (2002) 1295-1301
37. Zhanel G.G., Palatnick L., Nichol K.A., et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 47 6 (2003) 1867-1874
38. Powis J., McGeer A., Green K., et al. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob Agents Chemother 48 9 (2004) 3305-3311
39. Wierzbowski A.K., Swedlo D., Boyd D., et al. Molecular epidemiology and prevalence of macrolide efflux genes mef(A) and mef(E) in Streptococcus pneumoniae obtained in Canada from 1997 to 2002. Antimicrob Agents Chemother 49 3 (2005) 1257-1261
40. Hoban D.J., Wierzbowski A.K., Nichol K., et al. Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: Prevalence of mef(A) and erm(B) and susceptibilities to ketolides. Antimicrob Agents Chemother 45 7 (2001) 2147-2150
41. Farrel D.J., Morrissey I., Bakker S., et al. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother 50 Suppl S1 (2002) 39-47
42. Felmingham D., Reinert R.R., Hirakata Y., et al. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 50 Suppl S1 (2002) 25-37
43. Reinert R.R., Ringelstein A., van der Linden M., et al. Molecular epidemiology of macrolide-resistant Streptococcus pneumoniae isolates from Europe. J Clin Microbiol 43 3 (2005) 1294-1300
44. Farrell D.J., Morrissey I., Bakker S., et al. Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance. J Clin Microbiol 42 2 (2004) 764-768
45. Richter S.S., Heilmann K.P., Coffman S.L., et al. The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994-2000. Clin Infect Dis 34 (2002) 330-339
46. Munford R.S., and Murphy T.V. Antimicrobial resistance in Streptococcus pneumoniae: can immunization prevent its spread. J Investig Med 42 (1994) 613-621
47. Joloba M.L., Windau A., Bajaksouzian S., et al. Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media. Clin Infect Dis 333 (2001) 1498-2004
48. Pelton S.I., Daga R., Gaines B.M., et al. Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Interscience Conference on antimicrobial agents and chemotherapy. Vaccine 21 (2003) 1562-1571
49. McEllistrem M.C., Adams J.M., Patel K., et al. Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 40 (2005) 1738-1744
50. Lynch J.P., and Martinez F.J. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis 34 Suppl 1 (2002) S27-S46
51. Doern G.V. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin Infect Dis 33 Suppl 3 (2001) S187-S192
52. Vanderkooi O.G., Low D.E., Green K., et al. for the Toronto Invasive Bacterial Disease Network. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 40 (2005) 1288-1297
53. Beekmann SE, Diekema DJ, Heilmann KP, et al. Macrolide use identified as risk factor for macrolide-resistant Streptococcus pneumoniae in a 17-center case-control study. Eur J Clin Microbiol Infect Dis 2006. Available at: ==http://www.springerlink.com/openurl.asp?genre=article&id=. Accessed April 13, 2006.
54. Ghaffar F., Muniz L.S., Katz K., et al. Effects of large dosages of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, nonpneumococcal α-hemolytic streptococci, and Staphylococcus aureus in children with acute otitis media. Clin Infect Dis 34 (2002) 1301-1309
55. Diekema D.J., Brueggemann A.B., and Doern G.V. Antimicrobial-drug use and changes in resistance to Streptococcus pneumoniae. Emerg Infect Dis 6 5 (2000) 552-556
56. Bronzwaer S.L., Cars O., Buchholz U., et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 8 3 (2002) 278-282
57. García-Rey C., Aguilar L., Baquero F., et al. Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J Clin Microbiol 40 1 (2002) 159-164
58. Kristinsson K.G. Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci. Microb Drug Resist 3 2 (1997) 117-123
59. Hyde T.B., Gay K., Stephens D.S., et al. Macrolide resistance among invasive S pneumoniae isolates. JAMA 286 15 (2001) 1857-1862
60. Hennessy T.W., Petersen K.M., Bruden D., et al. Changes in antibiotic-prescribing practices and carriage of penicillin-resistant Streptococcus pneumoniae: a controlled intervention trial in rural Alaska. Clin Infect Dis 34 (2002) 1543-1550
61. Conte Jr. J.E., Golden J.A., Duncan S., et al. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob Agents Chemother 39 2 (1995) 334-338
62. Conte Jr. J.E., Golden J., Duncan S., et al. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob Agents Chemother 40 7 (1996) 1617-1622
63. Patel K.B., Xuan D., Tessier P.R., et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 40 10 (1996) 2375-2379
64. Rodvold K.A., Gotfried M.H., Danziger L.H., et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 41 6 (1997) 1399-1402
65. Guggenbichler J.P., and Kastner H. The influence of macrolide antibiotics on the fecal and oral flora. Infect Med 15 (1998) 17-25
66. Gray G.C., Witucki P.J., Gould M.T., et al. Randomized, placebo-controlled clinical trial of oral azithromycin prophylaxis against respiratory infections in a high-risk, young adult population. Clin Infect Dis 33 (2001) 983-989
67. Leach A.J., Shelby-James T.M., Mayo M., et al. A prospective study of the impact of community-acquired azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis 24 (1997) 356-362
68. Ghaffar F., Muniz L.S., Katz K., et al. Effects of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media. Clin Infect Dis 31 (2000) 875-880
69. Blondeau J.M. Differential impact of macrolide compounds in the selection of macrolide nonsusceptible Streptococcus pneumoniae. Therapy 2 6 (2005) 813-818
70. Doern G.V. Correspondence - reply to: Predicting the emergence of antimicrobial resistance. Clin Infect Dis 34 (2002) 1418-1420
71. Ambrose P.G. Antimicrobial susceptibility breakpoints; PK-PD and susceptibility breakpoints. Treat Respir Med 4 Suppl 1 (2005) 5-11
72. Lonks J.R., Garau J., Gomez L., et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 35 (2002) 556-564
73. Van Kerkhoven D., Peetermans W.E., Verbist L., et al. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral β-lactams. J Antimicrob Chemother 51 (2003) 691-696
74. Kelley M.A., Weber D.J., Gilligan P., et al. Breakthrough pneumococcal bacteremia treated with azithromycin and clarithromycin. Clin Infect Dis 31 (2000) 1008-1011
75. Jacobs M.R. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. Clin Infect Dis 35 (2002) 565-569
76. Hoffman H.L., Klepser M.E., Ernst E.J., et al. Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. Antimicrob Agents Chemother 47 2 (2003) 739-746
77. Maglio D., Capitano B., Banevicius M.A., et al. Efficacy of clarithromycin against Streptococcus pneumoniae expressing mef(A)-mediated resistance. Int J Antimicrob Agents 23 (2004) 498-501
78. Noreddin A.M., Roberts D., Nichol K., et al. Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. Antimicrob Agents Chemother 46 12 (2002) 4029-4034
79. Nuermberger E., and Bishai W.R. The clinical significance of macrolide-resistant Streptococcus pneumoniae: it's all relative. Clin Infect Dis 38 (2004) 99-103